RxDoctor Payments Data

Shiva Annamalai, MD

Cardiovascular Disease · Scarborough, MENPI 1972915544

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (53.7%), food and beverage and education — rather than concentrated in one kind of arrangement. Abbott accounts for 85.2% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2023 at $2,266 and has fallen 88.5% since, to $262 in 2025. Among cardiovascular disease clinicians in ME with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,855in general payments, 2019–2025

Across 42 payments — averaging $91.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Edwards Lifesciences$224
  • AstraZeneca$156
  • Astellas Pharma US Inc$90
  • Abiomed$24
  • Pfizer$23
  • plus $54 from 3 others

What the payments were for

  • Travel & lodging$2,07254%
  • Food & beverage$1,59341%
  • Education$1905%

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,855 in reported general payments places this provider in the 90th percentile of 99 cardiovascular disease providers in Maine.

See all cardiovascular disease providers in Maine

Medicare billing

Part B allowed, 2024
$86,428
Medicare patients
810
Services billed
1,641

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban61$79,383
Metoprolol Succinate220$3,080
Atorvastatin Calcium256$2,612
Torsemide42$2,381
Rosuvastatin Calcium73$1,300
Ezetimibe66$1,193
Bumetanide16$919
Amlodipine Besylate116$692
Potassium Chloride36$674
Lisinopril98$557
Isosorbide Mononitrate ErIsosorbide Mononitrate65$537
Furosemide107$453
Carvedilol45$359
Losartan Potassium68$331
ClopidogrelClopidogrel Bisulfate18$278

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$23$79,38361 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 99 cardiovascular disease providers in Maine.

Other cardiovascular disease in Scarborough

See the full list for Maine

Where these figures come from

Is this you, or does something look wrong? →